Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699123 · ClinicalTrials.gov registry record · Phase 2
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
A Phase 2 study of Advanced Non-Small-Cell Lung Cancer, sponsored by Yale University.
- Active
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 1
- Study location
NCT04699123: Active Phase 2 study of Advanced Non-Small-Cell Lung Cancer, sponsored by Yale University.
NCT04699123 is a Phase 2 study of Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by Yale University. The registered enrollment target is 159 participants, below the 375-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04699123, a Phase 2 study of Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
Primary Outcome
To determine the objective response rate (ORR) using RECIST v1.1 to NC318 in arm 1a
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG NC318 800 mg
- DRUG NC318 400 mg
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
What the registry record for NCT04699123 still lists
NCT04699123 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 375-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Advanced Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04699123 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04699123 about?
NCT04699123 is a clinical study titled "The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer". This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
What is the current status of trial NCT04699123?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2021-02-04. Estimated completion is 2025-06-30.
What conditions does trial NCT04699123 study?
This clinical trial studies the following conditions: Advanced Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT04699123?
The interventions under investigation include: Pembrolizumab (DRUG), NC318 800 mg (DRUG), NC318 400 mg (DRUG).
Who is sponsoring clinical trial NCT04699123?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04699123 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04699123's enrollment target sits among peer trials
159 15th of 22 higher than 8 of 22 other Advanced Non-Small-Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Non-Small-Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
RECRUITING · Phase 2
-
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI